{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"no emesis and no rescue anti-emetic therapy","groups":[{"description":"aprepitant plus standard anti-emetic regimen\n\nAprepitant: Add aprepitant to anti-emetic regimen","id":"OG000","title":"Aprepitant"},{"description":"olanzapine plus standard anti-emetic regimen\n\nOlanzapine: add olanzapine to anti-emetic regimen","id":"OG001","title":"Olanzapine"},{"description":"aprepitant and olanzapine plus standard anti-emetic regimen\n\nAprepitant plus Olanzapine: add aprepitant and olanzapine to anti-emetic regimen","id":"OG002","title":"Aprepitant Plus Olanzapine"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"within 120 hours following melphalan administration; no emesis and no rescue therapy within 120 hours of melphalan administration (within 120 hours following last day of melphalan administration at baseline)","title":"Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}